Amgen Buys Rights From Human Genome

From Bloomberg News

Amgen Inc. of Thousand Oaks acquired rights from Human Genome Sciences Inc. to develop and sell potential treatments for cancer and immune deficiencies.

A statement by Human Genome didn't disclose the price. The potential treatments and tests are based on a gene identified by the company.

Copyright © 2019, Los Angeles Times
EDITION: California | U.S. & World